Gilead invests $320M in Arcus to increase stake to 33%

Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration.

An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology strategy are among the considerations.